Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0APGMB |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | An antibody targeting CLDN6/9 |
|||||
| Antigen Name | CLDN6; CLDN9 |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
SC-004 [Phase 1 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | progressive disease (PD) |
21%
|
|||
| Patients Enrolled |
Eligible patients must have platinum-resistant ovarian or endometrial cancer (≤3 prior lines), ECOG 0-1, adequate organ function, with exclusion for prior PBD/IND-based therapy.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03138408 | Clinical Status | PHASE1 | ||
| Clinical Description |
An Open Label, Phase 1 Study of SC-004 as Monotherapy and in Combination With ABBV-181 in Subjects With Epithelial Ovarian, Including Fallopian Tube and Primary Peritoneal and Endometrial Cancers
|
||||
| Primary Endpoint |
Safety evaluation includes DLT assessment (NCI CTCAE v4.03) during the first 21-day cycle and QTcF monitoring over 9 weeks.
|
||||
| Other Endpoint |
PK parameters (Ctrough, Cmax, Tmax, T1/2, AUC) will be analyzed for 1 year; efficacy endpoints (ORR, CBR, PFS, OS, DOR, DOCB) will be tracked for 2 years.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | partial response (PR) |
5%
|
|||
| Patients Enrolled |
Eligible patients must have platinum-resistant ovarian or endometrial cancer (≤3 prior lines), ECOG 0-1, adequate organ function, with exclusion for prior PBD/IND-based therapy.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03138408 | Clinical Status | PHASE1 | ||
| Clinical Description |
An Open Label, Phase 1 Study of SC-004 as Monotherapy and in Combination With ABBV-181 in Subjects With Epithelial Ovarian, Including Fallopian Tube and Primary Peritoneal and Endometrial Cancers
|
||||
| Primary Endpoint |
Safety evaluation includes DLT assessment (NCI CTCAE v4.03) during the first 21-day cycle and QTcF monitoring over 9 weeks.
|
||||
| Other Endpoint |
PK parameters (Ctrough, Cmax, Tmax, T1/2, AUC) will be analyzed for 1 year; efficacy endpoints (ORR, CBR, PFS, OS, DOR, DOCB) will be tracked for 2 years.
|
||||
References